Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$542000.0.

  • Harvard Bioscience's Net Cash Flow fell 45894.04% to -$542000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 31245.38%. This contributed to the annual value of -$35000.0 for FY2024, which is 13684.21% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Net Cash Flow is -$542000.0, which was down 45894.04% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Net Cash Flow peaked at $2.4 million during Q4 2021, and registered a low of -$2.4 million during Q1 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$98000.0 (2024), whereas its average is -$91000.0.
  • Per our database at Business Quant, Harvard Bioscience's Net Cash Flow plummeted by 91625.0% in 2021 and then surged by 79349.59% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Net Cash Flow stood at $2.4 million in 2021, then crashed by 112.15% to -$286000.0 in 2022, then crashed by 205.59% to -$874000.0 in 2023, then surged by 88.79% to -$98000.0 in 2024, then plummeted by 453.06% to -$542000.0 in 2025.
  • Its Net Cash Flow stands at -$542000.0 for Q3 2025, versus $1.3 million for Q2 2025 and $1.1 million for Q1 2025.